Bamlanivimab and etesevimab combination has been authorised under Emergency Use Authorisation in the US and select EU countries for the treatment of the disease.
Eli Lilly and Company India on Tuesday said it has received permission for emergency use of its antibody drugs combination used for treatment of mild to moderate Covid-19, in the country. The company has received permission for restricted emergency use of its monoclonal antibody drugs, bamlanivimab 700 mg and etesevimab 1400 mg, used together for the treatment of patients with mild to moderate Covid-19, Eli Lilly said in a statement. Lilly is engaging in active dialogue with the Indian government and regulatory authorities to donate bamlanivimab and etesevimab in order to speed up access and provide treatment options for patients with Covid-19, it added.
Lilly is engaging in dialogue with government and regulatory authorities to donate bamlanivimab and etesevimab to speed up access and provide treatment options for patients with COVID-19, says the company